These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658 [TBL] [Abstract][Full Text] [Related]
3. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. Fabbiani M; Di Giambenedetto S; Ragazzoni E; Colafigli M; Prosperi M; Cauda R; Navarra P; De Luca A HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407 [TBL] [Abstract][Full Text] [Related]
4. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993 [TBL] [Abstract][Full Text] [Related]
5. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. Winston A; Bloch M; Carr A; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972 [TBL] [Abstract][Full Text] [Related]
12. Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics. Moyle G; Else L; Jackson A; Back D; Yapa MH; Seymour N; Ringner-Nackter L; Karolia Z; Gazzard B; Boffito M Antimicrob Agents Chemother; 2013 Aug; 57(8):3640-4. PubMed ID: 23689708 [TBL] [Abstract][Full Text] [Related]
13. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1. Rodríguez Nóvoa S; Barreiro P; Rendón A; Barrios A; Corral A; Jiménez-Nacher I; González-Lahoz J; Soriano V Clin Infect Dis; 2006 Jan; 42(2):291-5. PubMed ID: 16355344 [TBL] [Abstract][Full Text] [Related]
14. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. Smith DE; Jeganathan S; Ray J HIV Clin Trials; 2006; 7(1):34-8. PubMed ID: 16632461 [TBL] [Abstract][Full Text] [Related]
15. Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1. van Leeuwen E; Ter Heine R; van der Veen F; Repping S; Beijnen JH; Prins JM Antimicrob Agents Chemother; 2007 Jan; 51(1):335-7. PubMed ID: 17074793 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir. Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study. Martin DE; Galbraith H; Schettler J; Ellis C; Doto J Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835 [TBL] [Abstract][Full Text] [Related]
18. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. Ripamonti D; Cattaneo D; Maggiolo F; Airoldi M; Frigerio L; Bertuletti P; Ruggeri M; Suter F AIDS; 2007 Nov; 21(18):2409-15. PubMed ID: 18025877 [TBL] [Abstract][Full Text] [Related]